Evidence map›Paper›PMID 40949684›Full record

ArticleAnnals of translational medicine2025

Intense light as potential future therapy for myocardial injury in patients after non cardiac surgery: lessons from mice and men.

Julia Bertazzo, Yoshimasa Oyama, Finneas Gordon, Lori Walker, Tobias de la Garza Eckle

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Light therapy in medicine: where do we stand?Annals of translational medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Julia Bertazzo *Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Yoshimasa Oyama *Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Finneas GordonDepartment of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Lori WalkerDivision of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Tobias de la Garza EckleDepartment of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID https://orcid.org/0000-0002-6065-4669

Funding

NHLBI NIH HHS R01 HL122472NHLBI NIH HHS R56 HL156955
6 · The paper itself

Abstract

Background: Studies on light-elicited endothelial period circadian regulator 2 (PER2) mediated cardioprotection revealed a critical role of PER2/hypoxia inducible factor 1 alpha (HIF1A) regulated endothelial factor ANGPTL4 for endothelial barrier protection during myocardial ischemia and reperfusion injury (IRI). Based on these observations, we deepened our studies on light-elicited cardioprotective mechanisms. Methods: All animal and human studies had Institutional Animal Care and Use Committee (IACUC) and Colorado Multiple Institutional Review Board (COMIRB) approval. To study myocardial IRI, an in-situ mouse model for myocardial IRI was used. To study light-elicited mechanisms during myocardial IRI, endothelial-specific Results: The PER2 enhancer NOB or the HIF1A activator DMOG protected from myocardial IRI, which was abolished in endothelial-specific Conclusions: Our study demonstrates that only the PER2/HIF1A downstream target ANGPTL4 can overcome an endothelial

Indexed as

ANGPTL4light therapyMyocardial injury in non-cardiac surgery (MINS)myocardial ischemia (MI)

Identifiers

PMID40949684
PMCPMC12432674

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.